Online Only Articles

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, New York, NJ USA
Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark;Department of Biomedicine, Aarhus University, Aarhus, Denmark;Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
Kuros Biosciences BV, Bilthoven, the Netherlands
Kuros Biosciences BV, Bilthoven, the Netherlands;The School of Engineering and Materials Science, Queen Mary University of London, London, UK
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
Vol. 105 No. 2 (2020): February, 2020 https://doi.org/10.3324/haematol.2018.213314